Related Experiment Videos
Combined modality therapy for stage I-II large cell lymphoma
B R Prestidge1, S J Horning, R T Hoppe
1Department of Therapeutic Radiology, Stanford University Medical Center, CA 94305.
International Journal of Radiation Oncology, Biology, Physics
|September 1, 1988
Summary
This study on large cell lymphoma found that combining chemotherapy (CTX) and irradiation (XRT) achieved a 74% 5-year survival rate. The CTX-XRT-CTX therapy sequence significantly improved outcomes, with no relapses in patients receiving this approach.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Large cell lymphoma (LCL) is an aggressive non-Hodgkin lymphoma.
- Effective treatment strategies for localized LCL are crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of combined chemotherapy (CTX) and irradiation (XRT) in patients with Stage I-II large cell lymphoma.
- To identify prognostic factors influencing treatment outcomes in localized LCL.
Main Methods:
- Retrospective analysis of 94 patients with Stage I-II LCL treated between 1978-1986.
- Treatment involved combination CTX (e.g., CHOP) and involved or extended field XRT.
- Patients received CTX-XRT-CTX sequential therapy or other treatment regimens.
Main Results:
- 5-year actuarial survival and freedom from relapse (FFR) were 74% and 72%, respectively.
- The CTX-XRT-CTX sequence was associated with a favorable outcome (p=0.001), with no relapses observed in this subgroup.
- Low LDH and small tumor bulk were also favorable prognostic indicators.
Conclusions:
- Combined CTX and XRT is an effective treatment for localized large cell lymphoma.
- The sequential CTX-XRT-CTX therapy approach demonstrates superior outcomes and warrants further investigation.
- This study provides a benchmark for comparing single-modality treatment programs.